Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Avenet

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Journal of Receptor and Signal Transduction Research|January 1, 1997
Development of stable cell lines expressing different subtypes of GABAA receptorsF Besnard, Y Even, V Itier, et al.
European Journal of Pharmacology|January 25, 1996
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytesP Avenet, J Léonardon, F Besnard, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 16, 2011
The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2)B Biton, S Sethuramanujam, Kelly E Picchione, et al.
Journal of Affective Disorders|May 20, 1999
Preclinical profile of befloxatone, a new reversible MAO-A inhibitorO Curet, G Damoiseau-Ovens, C Sauvage, et al.
Molecular Pharmacology|June 1, 1995
Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoinP Granger, B Biton, C Faure, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptorsG Griebel, G Perrault, J Simiand, et al.
Neuroscience|August 12, 2008
Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profileY Claustre, M Leonetti, V Santucci, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2003
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationC Cohen, O E Bergis, F Galli, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Journal of Receptor and Signal Transduction Research|January 1, 1997
Development of stable cell lines expressing different subtypes of GABAA receptorsF Besnard, Y Even, V Itier, et al.
European Journal of Pharmacology|January 25, 1996
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytesP Avenet, J Léonardon, F Besnard, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 16, 2011
The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2)B Biton, S Sethuramanujam, Kelly E Picchione, et al.
Journal of Affective Disorders|May 20, 1999
Preclinical profile of befloxatone, a new reversible MAO-A inhibitorO Curet, G Damoiseau-Ovens, C Sauvage, et al.
Molecular Pharmacology|June 1, 1995
Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoinP Granger, B Biton, C Faure, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 17, 2001
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptorsG Griebel, G Perrault, J Simiand, et al.
Neuroscience|August 12, 2008
Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profileY Claustre, M Leonetti, V Santucci, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2003
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationC Cohen, O E Bergis, F Galli, et al.
Pageof 3